Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)
Public ClinicalTrials.gov record NCT05329545. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants With Recurrent, Platinum-Sensitive, Ovarian Cancer (UP-NEXT)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
UP-NEXT is a double-blind, randomized, placebo-controlled study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks in patients with recurrent, platinum-sensitive high-grade serous ovarian cancer (HGSOC), including fallopian tube and primary peritoneal cancer, expressing high levels of NaPi2b.
Study identification
- NCT ID
- NCT05329545
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 20 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 23, 2022 (Actual)
- Primary completion
- Sep 29, 2023 (Actual)
- Completion
- Sep 29, 2023 (Actual)
- Last update posted
- Oct 26, 2023
2022 – 2023
United States locations
- U.S. sites
- 28
- U.S. states
- 18
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| HonorHealth Research Institute - HonorHealth VGPCC Biltmore | Phoenix | Arizona | 85016 | — |
| The University of Arizona Cancer Center | Tucson | Arizona | 85719 | — |
| University of California Los Angeles, Gynecologic Oncology Clinic | Los Angeles | California | 90095 | — |
| University of California, Irvine Medical Center | Orange | California | 92868 | — |
| Sarasota Memorial Hospital | Sarasota | Florida | 34239 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| WK Physicians | Shreveport | Louisiana | 71103 | — |
| Karmanos Cancer Institute - Detroit | Detroit | Michigan | 48201 | — |
| Billings Clinic | Billings | Montana | 59101 | — |
| Methodist Hospital | Omaha | Nebraska | 68114 | — |
| Women's Cancer Center of Nevada | Las Vegas | Nevada | 89106 | — |
| Center of Hope | Reno | Nevada | 89433 | — |
| University of New Mexico Cancer Center | Albuquerque | New Mexico | 87106 | — |
| Southwest Women's Oncology | Albuquerque | New Mexico | 87109 | — |
| University Hospitals Cleveland Medical Center, Seidman Cancer Center | Cleveland | Ohio | 44106 | — |
| Kettering Health Cancer Center | Kettering | Ohio | 45429 | — |
| Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Willamette Valley Cancer Institute and Research Center | Eugene | Oregon | 97401 | — |
| Legacy Good Samaritan Medical Center - Legacy Medical Group - Gynecologic Oncology | Portland | Oregon | 97210 | — |
| Asplundh Cancer Pavilion | Willow Grove | Pennsylvania | 19090 | — |
| Sanford Gynecologic Oncology | Sioux Falls | South Dakota | 57104 | — |
| Avera McKennan d/b/a Avera Research Institute | Sioux Falls | South Dakota | 57105 | — |
| Texas Oncology P.A. - Austin | Austin | Texas | 78745 | — |
| Texas Oncology - DFWW | Bedford | Texas | 76022 | — |
| Texas Oncology - Tyler | Tyler | Texas | 75702 | — |
| VCU Massey Cancer Center | Richmond | Virginia | 23291 | — |
| University of Wisconsin Clinical Science Center | Madison | Wisconsin | 53792 | — |
| Froedtert Hospital and the Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05329545, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 26, 2023 · Synced Nov 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05329545 live on ClinicalTrials.gov.